Clinical Trial Update: SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating SHR-A1811 plus pertuzumab as neoadjuvant therapy for HER2-positive breast cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pertuzumab (pertuzumab)
• SHR-A1811

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Phase 2 | Status: RECRUITING